|Open mesh versus laparoscopic mesh repair of inguinal hernia|
L Neumayer, A Giobbie-Hurder, O Jonasson, R Fitzgibbons Jr, D Dunlop, ...
New England journal of medicine 350 (18), 1819-1827, 2004
|An immunogenic personal neoantigen vaccine for patients with melanoma|
PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ...
Nature 547 (7662), 217-221, 2017
|Does increased access to primary care reduce hospital readmissions?|
M Weinberger, EZ Oddone, WG Henderson
New England Journal of Medicine 334 (22), 1441-1447, 1996
|Adjuvant exemestane with ovarian suppression in premenopausal breast cancer|
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ...
New England Journal of Medicine 371 (2), 107-118, 2014
|Adjuvant ovarian suppression in premenopausal breast cancer|
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...
New England Journal of Medicine 372 (5), 436-446, 2015
|Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer|
BIG 1-98 Collaborative Group
New England Journal of Medicine 361 (8), 766-776, 2009
|Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial|
RJ Fitzgibbons, A Giobbie-Hurder, JO Gibbs, DD Dunlop, DJ Reda, ...
Jama 295 (3), 285-292, 2006
|Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin|
FS Hodi, CL Corless, A Giobbie-Hurder, JA Fletcher, M Zhu, ...
Journal of clinical oncology 31 (26), 3182, 2013
|Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …|
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
|Bevacizumab plus ipilimumab in patients with metastatic melanoma|
FS Hodi, D Lawrence, C Lezcano, X Wu, J Zhou, T Sasada, W Zeng, ...
Cancer immunology research 2 (7), 632-642, 2014
|The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition|
X Jiang, J Zhou, A Giobbie-Hurder, J Wargo, FS Hodi
Clinical cancer research 19 (3), 598-609, 2013
|Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International …|
G Viale, A Giobbie-Hurder, MM Regan, AS Coates, MG Mastropasqua, ...
Journal of clinical oncology 26 (34), 5569, 2008
|Effectiveness of team-managed home-based primary care: a randomized multicenter trial|
SL Hughes, FM Weaver, A Giobbie-Hurder, L Manheim, W Henderson, ...
Jama 284 (22), 2877-2885, 2000
|Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis|
M Nishino, A Giobbie-Hurder, H Hatabu, NH Ramaiya, FS Hodi
JAMA oncology 2 (12), 1607-1616, 2016
|Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements|
M Nishino, A Giobbie-Hurder, M Gargano, M Suda, NH Ramaiya, FS Hodi
Clinical cancer research 19 (14), 3936-3943, 2013
|Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome|
LB Gordon, ME Kleinman, DT Miller, DS Neuberg, A Giobbie-Hurder, ...
Proceedings of the National Academy of Sciences 109 (41), 16666-16671, 2012
|Osteoporosis and risk of fracture in men with spinal cord injury|
MG Lazo, P Shirazi, M Sam, A Giobbie-Hurder, MJ Blacconiere, ...
Spinal cord 39 (4), 208-214, 2001
|Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial|
DB Keskin, AJ Anandappa, J Sun, I Tirosh, ND Mathewson, S Li, ...
Nature 565 (7738), 234-239, 2019
|Relationship between caregiver burden and health-related quality of life|
SL Hughes, A Giobbie-Hurder, FM Weaver, JD Kubal, W Henderson
The Gerontologist 39 (5), 534-545, 1999
|Challenges of guarantee-time bias|
A Giobbie-Hurder, RD Gelber, MM Regan
Journal of clinical oncology 31 (23), 2963, 2013